A novel antiallergic drug epinastine inhibits IL-8 release from human eosinophils.
Eosinophils are believed to be one of the important sources of cytokines at the site of allergic inflammation. A novel antiallergic agent epinastine showed a dose- and time-dependent suppressive effect on IL-8, one of the chemokines for eosinophils, released from eosinophils isolated from atopic diseases. The time-dependent accumulation of IL-8 inhibited by cycloheximide and the evaluation of the IL-8 mRNA levels by reverse transcriptase-polymerase chain reaction suggested that its action occurred in the posttranscriptional processes. It was suggested that epinastine might prevent the autocrine cycle for recruitment of human eosinophils by inhibiting IL-8 release from these cells.
Kohyama
T
T
Department of Medicine and Physical Therapy, University of Tokyo, School of Medicine, Bunkyo-ku, Japan.
Takizawa
H
H
Akiyama
N
N
Sato
M
M
Kawasaki
S
S
Ito
K
K
D000001:Calcimycin / Q000494:pharmacology; D002478:Cells, Cultured; D018946:Chemokine CCL5 / Q000096:biosynthesis; D017931:DNA Primers; D003984:Dibenzazepines / Q000494:pharmacology*; D004797:Enzyme-Linked Immunosorbent Assay; D004804:Eosinophils / Q000187:drug effects / Q000276:immunology*; D006634:Histamine H1 Antagonists / Q000494:pharmacology*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D016209:Interleukin-8 / Q000096:biosynthesis* / Q000097:blood; D007700:Kinetics; D016133:Polymerase Chain Reaction; D014158:Transcription, Genetic / Q000187:drug effects
D018946:Chemokine CCL5; D017931:DNA Primers; D003984:Dibenzazepines; D006634:Histamine H1 Antagonists; D007093:Imidazoles; D016209:Interleukin-8; D000001:Calcimycin; C053090:epinastine